A biopharmaceutical company, focused on developing small molecule therapeutics for the treatment of cardiovascular diseases and cancer.


Updates from The Motley Fool

Latest updates on Cytokinetics from Fool.com.
This Week in Biotech

A buyout that appears to be a screaming deal and data from four clinical-stage studies dominate t...

These Underdogs Are No Dogs

Like the smart hedge fund operators, these CAPS investors bet against a stock -- and won big!

3 Top Stocks at Half-Price

Investors still think highly of these companies, despite their fire-sale prices.



Stock Performance

View Interactive CYTK Charts
Sponsored by

Key Data Points

Primary metrics and data points about Cytokinetics.
Current Price: $14.50
Prev Close: $13.85
Open: $14.00
Bid: $14.30
Ask: $15.15
Day's Range: $13.85 - $14.50
52wk Range: $8.51 - $17.20
Volume: 347,661
Avg Vol 499,029
Market Cap: $655M
P/E (ttm): 138.50
EPS (ttm): $0.10
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Cytokinetics.
CAPS Rating 2 out of 5
 
162 Outperform
18 Underperform
CAPS All Stars
 
33 Outperform
6 Underperform

How do you think Cytokinetics will perform against the market?



You pick for Cytokinetics is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Robert I. Blum, CEO

78% Approve

Based on 7 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Cytokinetics.

A biopharmaceutical company, focused on developing small molecule therapeutics for the treatment of cardiovascular diseases and cancer.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers